... Mar 23
Cornerstone Robotics , a leading global innovator in surgical robotics, is pleased to announce the closing of an oversubscribed new financing round of approximately US$200 ... Nov 14
These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 ... Oct 31
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen ... Oct 15
Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study of etrasimod for the treatment of subjects with moderately ... Oct 10
Hong Kong’s healthcare sector surged by nearly 30% in the last decade, with the total number of related businesses now exceeding 3,000.... Sep 17
In the first half of 2025, the industry continued to face challenges from global geopolitical uncertainties and evolving domestic centralised procurement dynamics. However, supportive government ... Sep 01
According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its ... Aug 21
Essex Bio-Technology Limited is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal ... Aug 16
... Aug 16
Everest Medicines recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R).... Aug 12
Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,... Jul 28
In 2025, the policies regarding traditional Chinese medicine (TCM) in Mainland China are being continuously optimized, providing broader opportunities for the consumer TCM market. ... Jun 03
Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).... May 08
... Apr 15
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for ... Jan 03
CanSinoBIO will continue to drive the innovation and development of vaccines with a global vision by enhancing collaboration with international partners, and contributing more to ... Apr 29
Latest Pharma news updates... Nov 02
Latest pharma news update... Sep 27
Latest Pharma News update... Sep 03
Latest Pharma News Update... Aug 31
This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first ... Jun 23
Sorrento intends to combine a variety of its proprietary mAbs in conjunction with the ADNAB technology platform... Apr 28
Surgery is currently the most common treatment option for the treatment of NMSC which often carry significant cutaneous adverse events, risk of scar, infection, bleeding ... Apr 27
-Advertisements-
.jpeg)
Sunday, July 12, 2026
.png)
.png)
.png)
.png){kind=logo}
.png)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)